Close

Halozyme Therapeutics (HALO) Reports FDA Approval of Herceptin Hylecta

February 28, 2019 11:49 AM EST Send to a Friend
Halozyme Therapeutics, Inc. (NASDAQ: HALO) has received approval from the U.S. Food and Drug Administration (FDA) for Herceptin Hylectaâ„¢, a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login